Please login to the form below

Not currently logged in

Novartis claims first CAR-T approval, setting $475k price tag

Kymriah receives FDA nod to treat ALL patients


The FDA has approved Novartis’ cancer immunotherapy tisagenleucel (CTL019) under the Kymriah brand name, setting a $475,000 price per course for the chimeric antigen receptor T cell (CAR-T) therapy.

Kymriah is the first in a new generation of treatments that rely on reprogramming patients’ own white blood cells to attack malignant cells, and has also been billed by the regulator as the first gene therapy to be approved in the US. Its approval comes after an FDA advisory committee backed the drug by a unanimous vote last month.

FDA commissioner Scott Gottlieb said the approval ushers in “a new frontier in medical innovation”, adding: “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

The agency has approved Kymriah for paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory to treatment or in second or later relapse. Most ALL patients respond to initial therapy, but Kymriah will be an invaluable back-up option for relapsed and refractory patients who currently have poor prognosis. In trials, the therapy achieved remission in 83% of patients.

It is not without risks, however, as CAR-T therapies can cause serious side effects such as cytokine release syndrome which can be life-threatening. Novartis has agreed a risk evaluation and mitigation strategy (REMS) with the FDA that amongst other things will see the therapy delivered only at certified treatment centres. Meanwhile, this week Roche secured FDA approval to use its arthritis drug Actemra (tocilizumab) as a treatment for CAR-T-induced CRS.

The high cost of the therapy reflects the fact that the CAR-T procedure is fairly intensive. Cells are removed from the patient, modified to target cancer cells and expanded outside the body, and then re-infused into the patient. A report in the Financial Times suggests the cost of goods for Kymriah comes in at around $200,000 per patient.

Novartis has suggested it will however develop a flexible pricing strategy for the therapy that will be based on the outcome of therapy, and with payment only becoming due when ALL patients have responded to Kymriah “by the end of the first month”. Some commentators have suggested this does not go far enough however, arguing that the company should seek payment only after a longer relapse-free period.

While there has been some exploratory work on re-treating with CAR-T therapies, they are currently considered a one-time therapy. Recent research has suggested that the modified T cells have the potential to re-activate if a cancer re-emerges.

Novartis said it plans to file for approval of Kymriah in the EU later this year, and is also preparing for follow-up indications such as diffuse large B-cell lymphoma (DLBCL).

Another CAR-T candidate - Kite Pharma's KTE-C19 (axicabtagene ciloleucel) for DLBCL - is under review and due for an FDA decision in November. The potential of the drug and CAR-T follow-ups prompted Gilead Sciences to agree a $11.9bn takeover deal for Kite earlier this week.

Article by
Phil Taylor

31st August 2017

From: Regulatory



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...